ClinicalTrials.gg
CompletedNCT00136968Updated Mar 12, 2009

Assessment of Voriconazole Penetration Into the Brain by Fluorine-Magnetic Resonance Spectroscopy

A Phase 1 interventional study of Voriconazole in Fungal Infection, sponsored by Pfizer. Completed. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2009-03-12.

Sponsored by Pfizer · Phase 1 and Interventional

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
12
Allocation
Non-randomized
Ages
18 Years to 55 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 17 studies testing voriconazole in Mycoses — none open to participants now, none under way, none of them phase 3. Voriconazole · Mycoses.

Enrollment
15th of 17
12 · median 29
Started
2005
the only one that year
Phase 1
5 of 17
none open now
Registered
6th of 17
by date
Lead sponsor
3 of 17
Pfizer

Among the 17 studies testing voriconazole in Mycoses, this one is the 15th largest by enrollment, is the only one that started in 2005, is one of 5 in phase 1, and was the 6th registered.

Mycoses

260 studies on the registry are indexed under Mycoses; 37 are open to participants now.

Browse Mycoses studies →

Open to participants now

None of the 17 studies testing voriconazole in Mycoses is open now. The open studies under Mycoses, anywhere →

About voriconazole

Voriconazole: first FDA approval 2002 (VFEND), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 24 Mycoses studies recruiting now, 13 (54%) set no upper age limit and 4 (17%) stop at 75 or younger; 5 take children under 18; 6 take healthy volunteers.

This study: 18 Years to 55 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 17 studies testing voriconazole in Mycoses as a file.
02

Study summary

The purpose of this study is to determine the amount of voriconazole in the brain by fluorine-magnetic resonance spectroscopy (MRS) and to compare brain levels to plasma levels.

03

Conditions studied

  • Fungal Infection

Browse trials for

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male volunteers 18-55 years of age

Exclusion criteria

Exclusion Criteria:

  • Subjects with any condition affecting drug absorption
  • Subjects with a positive urine drug screen
05

Study design

Phase
Phase 1
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
12 participants (actual)

Interventions

06

What researchers measure

Primary outcomes

  1. Assess brain levels of voriconazole in the brain using a non-evasive technique of MRS

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2005 and a completion of May 2005. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 25, 2005
First posted
Aug 29, 2005
Start
Apr 2005
CompletionActual
May 2005
Last update
Mar 12, 2009
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 12, 2009, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00136968
Lead sponsor
Pfizer
Collaborators
Mclean Hospital
First posted
Aug 29, 2005
Start date
Apr 2005
Completion
May 2005
Last update
Mar 12, 2009

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2009. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Voriconazole

Start the discussion